Premium
P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812
Author(s) -
Schneider Lon S.,
Caggiano Anthony O.,
Grundman Michael,
DeKosky Steve,
Morgan Roger,
Mozzoni Kelsie,
Izzo Nicholas J.,
Safferstein Hank,
Catalano Susan
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.09.072
Subject(s) - neurogranin , placebo , medicine , receptor , biomarker , endocrinology , synapse , pharmacology , chemistry , pathology , biochemistry , enzyme , neuroscience , biology , alternative medicine , protein kinase c
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom